245 related articles for article (PubMed ID: 21552290)
21. Dermal cylindromas (turban tumour) and eccrine spiradenomas in a patient with membranous basal cell adenoma of the parotid gland.
Ferrándiz C; Campo E; Baumann E
J Cutan Pathol; 1985 Feb; 12(1):72-9. PubMed ID: 2982934
[TBL] [Abstract][Full Text] [Related]
22. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
23. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.
Wickström SA; Masoumi KC; Khochbin S; Fässler R; Massoumi R
EMBO J; 2010 Jan; 29(1):131-44. PubMed ID: 19893491
[TBL] [Abstract][Full Text] [Related]
24. Five novel germline function-impairing mutations of CYLD in Italian patients with multiple cylindromas.
Nasti S; Pastorino L; Bruno W; Gargiulo S; Battistuzzi L; Zavattaro E; Leigheb G; De Francesco V; Tulli A; Mari F; Scarrà GB; Ghiorzo P
Clin Genet; 2009 Nov; 76(5):481-5. PubMed ID: 19807742
[No Abstract] [Full Text] [Related]
25. Genetic evidence for selective neurotrophin 3 signalling through TrkC but not TrkB in vivo.
Stenqvist A; Agerman K; Marmigère F; Minichiello L; Ernfors P
EMBO Rep; 2005 Oct; 6(10):973-8. PubMed ID: 16142215
[TBL] [Abstract][Full Text] [Related]
26. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
[TBL] [Abstract][Full Text] [Related]
27. Expression of trkA, trkB, and trkC in injured and regenerating retinal ganglion cells of adult rats.
Cui Q; Tang LS; Hu B; So KF; Yip HK
Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):1954-64. PubMed ID: 12037005
[TBL] [Abstract][Full Text] [Related]
28. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors.
Fukuda M; Fukuda F; Horiuchi Y; Oku Y; Suzuki S; Kusama K; Sakashita H
In Vivo; 2006; 20(4):467-72. PubMed ID: 16900776
[TBL] [Abstract][Full Text] [Related]
29. Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
Danilenko M; Stamp E; Stocken DD; Husain A; Zangarini M; Cranston A; Stones R; Sinclair N; Hodgson K; Bowett SA; Roblin D; Traversa S; Plummer R; Veal G; Langtry JAA; Ashworth A; Burn J; Rajan N
JAMA Dermatol; 2018 Aug; 154(8):913-921. PubMed ID: 29955768
[TBL] [Abstract][Full Text] [Related]
30. Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction.
Rajan N; Langtry JA; Ashworth A; Roberts C; Chapman P; Burn J; Trainer AH
Arch Dermatol; 2009 Nov; 145(11):1277-84. PubMed ID: 19917957
[TBL] [Abstract][Full Text] [Related]
31. Identification of a large rearrangement in CYLD as a cause of familial cylindromatosis.
van den Ouweland AM; Elfferich P; Lamping R; van de Graaf R; van Veghel-Plandsoen MM; Franken SM; Houweling AC
Fam Cancer; 2011 Mar; 10(1):127-32. PubMed ID: 20972631
[TBL] [Abstract][Full Text] [Related]
32. Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours.
Li Y; Wei C; Wang W; Li Q; Wang ZC
J Pathol Clin Res; 2023 Mar; 9(2):89-99. PubMed ID: 36533776
[TBL] [Abstract][Full Text] [Related]
33. A mutational hotspot in CYLD causing cylindromas: a comparison of phenotypes arising in different genetic backgrounds.
Nagy N; Rajan N; Farkas K; Kinyó A; Kemény L; Széll M
Acta Derm Venereol; 2013 Nov; 93(6):743-5. PubMed ID: 23584127
[No Abstract] [Full Text] [Related]
34. Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells.
Lawn S; Krishna N; Pisklakova A; Qu X; Fenstermacher DA; Fournier M; Vrionis FD; Tran N; Chan JA; Kenchappa RS; Forsyth PA
J Biol Chem; 2015 Feb; 290(6):3814-24. PubMed ID: 25538243
[TBL] [Abstract][Full Text] [Related]
35. Trichoepitheliomas and eccrine spiradenomas with spiradenoma/cylindroma overlap.
Bumgardner AC; Hsu S; Nunez-Gussman JK; Schwartz MR
Int J Dermatol; 2005 May; 44(5):415-7. PubMed ID: 15869542
[No Abstract] [Full Text] [Related]
36. Phenotype variability in tumor disorders of the skin appendages associated with mutations in the CYLD gene.
Parren LJMT; Giehl K; van Geel M; Frank J
Arch Dermatol Res; 2018 Sep; 310(7):599-606. PubMed ID: 29974194
[TBL] [Abstract][Full Text] [Related]
37. New mutation in the CYLD gene within a family with Brooke-Spiegler syndrome.
Scholz IM; Nümann A; Froster UG; Helmbold P; Enk AH; Näher H
J Dtsch Dermatol Ges; 2010 Feb; 8(2):99-101. PubMed ID: 20151946
[TBL] [Abstract][Full Text] [Related]
38. Intracellular LINGO-1 negatively regulates Trk neurotrophin receptor signaling.
Meabon JS; de Laat R; Ieguchi K; Serbzhinsky D; Hudson MP; Huber BR; Wiley JC; Bothwell M
Mol Cell Neurosci; 2016 Jan; 70():1-10. PubMed ID: 26546150
[TBL] [Abstract][Full Text] [Related]
39. Neurotrophin receptors expression and JNK pathway activation in human astrocytomas.
Assimakopoulou M; Kondyli M; Gatzounis G; Maraziotis T; Varakis J
BMC Cancer; 2007 Oct; 7():202. PubMed ID: 17971243
[TBL] [Abstract][Full Text] [Related]
40. PLAG1 and CYLD do not play a role in the tumorigenesis of adenoid cystic carcinoma.
Daa T; Nakamura I; Yada N; Arakane S; Nishida H; Kashima K; Suzuki M; Yokoyama S
Mol Med Rep; 2013 Apr; 7(4):1086-90. PubMed ID: 23404581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
